U.S. Defense Secretary Pete Hegseth announced a new policy requiring annual testosterone level screenings for certain military personnel. Under the directive, all active-duty and reserve service members aged 30 and older will undergo mandatory testing as part of their annual health assessments. Personnel under age 30 will have the option to voluntarily participate in the screenings.
The policy follows Hegseth’s stated goal of maintaining what he termed a "High-T Department of War." Hegseth said the initiative is intended to help service members restore and optimize natural capabilities and provide the biological foundation needed for military service. He emphasized that the program is not meant for artificial enhancement and that treatment will remain at the patient's discretion.
According to a July 15 statement from Pentagon spokesperson Sean Parnell, the screening protocols are now mandatory for the specified age groups. If a service member is found to have low testosterone, the Department of Defense will offer testosterone replacement therapy (TRT). Hegseth stated that individual patients will choose whether to proceed with the recommended medical treatment.
Medical consensus on what constitutes a "low" testosterone level varies based on factors including age, sex, and physical symptoms. The Endocrine Society notes that normal levels for adult men typically range from 300 to 1,000 nanograms per deciliter, while levels for women are significantly lower. Natural testosterone levels generally decline by 1% to 2% annually starting between ages 30 and 40.
Medical professionals typically diagnose testosterone deficiency, or hypogonadism, when low blood-test results are accompanied by specific physical symptoms. While TRT can address these symptoms, medical experts note that the therapy carries potential risks and that not all individuals with lower-than-average readings require clinical intervention.
For individual service members, the policy means their hormonal data will become a permanent part of their military medical record. While Hegseth stated that treatment remains voluntary, the inclusion of these metrics in annual readiness assessments may influence how personnel manage their long-term health and career longevity. The focus on "restoring and optimizing" biological capabilities suggests a move toward more proactive medical interventions within the armed forces.
The practical consequences extend to the military’s healthcare infrastructure and budget. Implementing a universal screening program for all members over 30 will require substantial logistics and funding for both the initial tests and any subsequent therapies. This sets a precedent for using hormonal benchmarks as a specific measure of combat readiness, a move that could eventually influence recruitment standards or benefit structures for veterans. The long-term effects on force health and the total cost to the Defense Department depend on the percentage of personnel who opt for treatment following their results.